IKT Inhibikase Therapeutics, Inc.: institutional ownership and insider trading
109 funds reported holding $249M of Inhibikase Therapeutics, Inc. in their latest 13F filings; in Q2 2026 funds net bought $7.89M, with 18 new positions and 14 funds selling out; over the last 12 months insiders bought $3.00M and sold $0 on the open market.
Famous investors holding IKT
- Izzy Englander (Millennium Management): $8.18M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $1.64M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $151K, 0.0% of the portfolio
Largest institutional holders of IKT
- Sands Capital Alternatives, LLC — $26.4M
- Soleus Capital Management, L.P. — $22.1M
- Trails Edge Capital Partners, LP — $18.4M
- Fairmount Funds Management LLC — $17.5M
- BlackRock, Inc. (BLK) — $15.8M
- ADAR1 Capital Management, LLC — $15.0M
- Blackstone Inc. (BX) — $12.1M
- Siren, L.L.C. — $11.9M
- Commodore Capital LP — $11.0M
- VANGUARD CAPITAL MANAGEMENT LLC — $10.0M
Recent IKT insider trades
- Nov 21, 2025: Sands Capital Alternatives, LLC bought 2,068,965 shares ($3.00M)
5%+ owners
- ADAR1 Capital Management, LLC: 9.9% (Schedule 13G/A, filed May 15, 2026)
- Commodore Capital LP: 9.9% (Schedule 13G/A, filed May 15, 2026)
- RA Capital Management, L.P.: 9.9% (Schedule 13G/A, filed Jul 31, 2026)
- Sands Capital Life Sciences Pulse Fund II, L.P.: 9.3% (Schedule 13G/A, filed Aug 13, 2026)
- Perceptive Advisors LLC: 6.9% (Schedule 13G/A, filed Aug 14, 2026)
- Trails Edge Capital Partners, LP: 6.1% (Schedule 13G/A, filed May 15, 2026)